41 results about "Paclitaxel Liposome" patented technology

The invention relates to a method for preparing drug rehabilitation liposome agent, which comprises that using film disperse method or atomizing drying method to prepare long-circulation rehabilitation liposome, using cholesterol, distearin acyl phosphatidyl choline and myristate as stabilizers, using sucrose as freezing preservative, using chloroform and chloroform as organic solvents; and using amphipathic carbowax derivative to decorate the liposome membrane; and using compression or high-pressure homogeneity method to make the diameter of liposome smaller than 100nm and the package rate higher than 85%. The invention has less toxicity and high stability, as one novel drug slow-release target agent.

The invention relates to a DSPE-PEG2000-FA-modified nanometer paclitaxel liposome. A molar ratio of the DSPE-PEG2000-FA to egg yolk lecithin is 0.05% to 0.15%, and a particle size of the liposome is less than 150 nm. A preparation method of the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome comprises the following steps: first, preparing a DSPE-PEG2000-FA into a DSPE-PEG2000-FA micelle; second, performing incubation on the phosphatidyl ethanolamine-polyethylene glycol2000-folic acid micelle and a paclitaxel liposome together to obtain a DSPE-PEG2000-FA-modified nanometer paclitaxel liposome. Materials, which are forbidden to be used in clinical practice, are not used as crude materials in the present invention. According to the invention, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome has a small particle size, and the content of the DSPE-PEG2000-FA is low; besides, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome has good drug entrapment efficiency and good colloid stability. Moreover, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome can be absorbed effectively by an ovarian cancer cell having properties of sensitiveness to folic acid (+) and drug resistance, and the cytotoxicity of folic acid dependence is displayed; therefore, the efficacy of the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome is stronger than that of a paclitaxel injection.

The invention discloses a novel lipid material which is used for prolonging the circulation time and increasing drug targets to be transmitted to the brain. According to the novel lipid material, polyethylene glycol is used for bridging, one side of polyethylene glycol is connected with cholesterol, and the other side of polyethylene glycol is connected with glucose and vitamin C, so that the defect of the targeting capability of lipidosomes modified by single glucose or vitamin C is made up for, transfer for crossing a blood-brain and blood-brain spinal fluid dual barrier is achieved, the brain targeting of drugs is improved, and the central concentration of the drugs is increased. The novel lipid material can be used for different dosage forms including liposomes, nanoparticles and micelles, and paclitaxel liposomes prepared from the material have an obvious brain targeting function and wide application prospects.

The invention discloses an integrin receptor target lipidosome drug carrier and a preparation method thereof, as well as an application of the drug carrier in preparing antitumor lipidosome drug. Hexadecyl fatty chain is conjugated with RGD peptide segment and is hydrophobic-modified so as to synthesize hexadecyl and RGD peptide conjugate with amphipathy, namely, Arg-Gly-Asp-X-NH-C16H33, and X is selected from valine, serine or phenylalanine. The invention introduces fat-soluble antitumor drug into the conjugate with amphipathy to obtain the antitumor target lipidosome drug, the lipidosome system can increase the concentration of the antitumor drug at the target and can reduce toxic and side effects of the antitumor drug to the non-target part, thereby improving the treatment index of the drug. The invention evaluates the antitumor activity of taxol lipidosome by using a Holland sarcoma S180 mouse as a model, the result shows that the taxol lipidosome has more excellent antitumor activity than each control group.

The invention relates to anti-rheumatoid arthritis drug gel containing paclitaxel liposome and a preparation method of the gel. The gel is prepared from main drugs and blank gel, wherein the main drugs comprise paclitaxel liposome and lidocaine hydrochloride; the mass volume ratio of the paclitaxel liposome to lidocaine hydrochloride is 5:100-20:100; and the mass volume ratio of lidocaine hydrochloride to the blank gel is 1:100-5:100. According to the requirements of evidence-based medicine, a drug paclitaxel for treating RA and lidocaine are compatible with each other, the paclitaxel is coated by utilizing a liposome technology, the bioavailability is improved, and the prepared gel suitable for directed use at an affected part is adopted. The gel achieves a treatment effect aiming at the pathogenesis of RA, and pain of a patient suffering from RA can be rapidly relieved. A novel therapy approach is provided for vast patients suffering from RA.

The invention provides a targeted nano-microbubble for treating small cell lung cancer, a preparation method and application thereof. Targeted nano-microbubbles include a lipid bimolecular shell and an inert gas wrapped inside the lipid bimolecular shell, and the anti-progastrin releasing peptide monoclonal antibody of small cell lung cancer and paclitaxel are connected to the lipid bimolecular shell, The average particle size of nano-microbubbles is 300-500nm. Preparation method: dipalmitolecithin, distearoylphosphatidylethanolamine, dipalmitophosphatidic acid and paclitaxel were completely dissolved in chloroform by film hydration method to prepare paclitaxel-containing liposomes, which are aimed at anti-progastrocytosis of small cell lung cancer The hormone-releasing peptide monoclonal antibody was opened with mercaptoethylamine, incubated with the liposome above to form a stable thioether bond, and then perfluoropropane gas was passed through, and the anti-monogastric antibody targeting small cell lung cancer was obtained by mechanical vibration. Secretin-releasing peptide monoclonal antibody targeting paclitaxel nanomicrobubbles. The targeted nanometer microbubble can be used in the preparation of medicines for treating small cell lung cancer.

The invention relates to a liposome drug combination and a preparation method of the drug combination. The weights of the effective drug components are listed as follows: the weight of the admixture for hydrogenated soybean phosphatide and sheep brain lecithin with a weight ratio of 2:1 is 300 to 550; the weight of the admixture for cholesterol, stearamide and beta-sitosterol with a weight ratio of 1:1:0.1 is 200 to 400; the weight of the admixture for tiopronin and vitamin E with a weight ratio of 4:1 is 100 to 200; the weight of the admixture for polyethylene glycol-4000 and polyethylene glycol-6000 with a discretional weight ratio is 150 to 200; the weight of vitamin C is 150 to 180; the weight of the admixture for tert-butyl alcohol and anhydrous alcohol with a weight ratio of 1.5 to 2.2:0.01 to 0.05 is 4000 to 7000; the weight of the admixture for paclitaxel and polyene paclitaxel with a discretional weight ratio is 20 and 40; the weight of the admixture for diphenhydramine and cimetidine with a weight ratio of 1:6 is 350 to 500. The invention has the advantages of reducing the drug dosage by nearly one time, increasing the curative effect by over 15 percent, and greatly reducing the side effect of the drugs.

The invention discloses novel lipid materials for realizing the delivery of breast cancer targeted drugs. According to the novel lipid materials, through a branch framework, one end is connected to cholesterol extended by polyethylene glycol, and the other end is connected to a different number of biotins with a breast cancer targeting function; and affinity between the novel lipid materials and areceptor can be used to realize stronger tumor targeting and play a more effective role in breast cancer treatment. The novel lipid materials can be used in different dosage forms such as liposomes,nanoparticles and micelles, and the prepared paclitaxel-loaded liposomes have obvious breast cancer targeting and broad application prospects.

The invention provides a protamine oligopeptide modified paclitaxel liposome and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The protamine oligopeptide modified paclitaxel liposome provided by the invention comprises the following raw materials of protamine oligopeptide LMWP, paclitaxel, lecithin, cholesterol and glucose. The protamine oligopeptide LMWP is combined with a liposome embedding technology, the operation is simple and convenient, the obtained paclitaxel liposome is stable in property and high in bioavailability, the average particle size is about 124.43 nm and is smaller than that of a common paclitaxel liposome, the zeta potential is -40.6 mV, and the storage stability is good. The water solubility of the protamine oligopeptide modified paclitaxel liposome is improved, the content of the paclitaxel liposome in cells is also increased accordingly, the paclitaxel liposome has the effect of enhancing the drug effect, and protamine can obviously reduce the density of blood vessels in tumors and has the anti-tumor effect.

The invention discloses a novel lipid material for realizing the delivery of a breast cancer targeted drug. The novel lipid material takes lysine as a connecting group and is connected with a cholesteric part, a biotin part and a glucose part. The affinity between biotin and glucose in the novel lipid material and biotin transporter (SMVT) and glucose transporter (GLUT1) can be utilized to realizethe double targeting function to breast cancer and play a stronger breast cancer targeting therapeutic role, wherein the biotin transporter (SMVT) and the glucose transporter (GLUT1) are highly expressed on the surface of breast cancer cells. The novel lipid material can be used in different dosage forms comprising liposomes, nanoparticles, micelles and the like, and the prepared paclitaxel-loaded liposome has obvious breast cancer targeting property and a wide application prospect.

The invention discloses a stir-frying technology for Chinese yew powder rich in paclitaxel liposome by using a membrane-ultrasonic wave dissolving technique, belonging to the technical field of medicines. According to the invention, a traditional stir-frying method for Chinese herbal medicines is combined with advanced preparation and enrichment technologies for paclitaxel (taxane) liposome so as to process the Chinese yew powder which is rich in the paclitaxel (taxane) liposome, can be easily absorbed in oral administration and has a high efficiency anticancer effect and low toxic and side effects. The method comprises the following concrete steps: putting 95% ethanol and egg oil which are used as liquid accessories and Chinese yew powder and Chinese yew extract powder which are used as stir-frying substrates in a membrane evaporator together, carrying out stir-frying under the conditions of a constant temperature (a water bath at a temperature of 60 DEG C), pressure reduction and continuous rotation operation, carrying out hydration so as to form the paclitaxel (taxane) liposome and allowing the paclitaxel (taxane) liposome to be enriched in Chinese yew powder particles by using a vacuum/pressure method, thereby allowing the Chinese yew powder to become an anticancer Chinese herbal medicine which is rich in the paclitaxel (taxane) liposome, can be easily absorbed in oral administration and has high efficiency and low toxic and side effects.

The invention relates to a method for preparing a hyaluronic acid oligosaccharide encased paclitaxel liposome. The method comprises the following steps of: weighing phospholipids and paclitaxel to prepare a phospholipids-paclitaxel honeycomb-type thin film; hydrating the prepared thin film; preincubating oligosaccharide and ethyl dimethyl amine propyl carbodiimide in an acetate buffering solution; adding the hydrated suspension into an oligosaccharide-acetate buffering solution for incubation; and separating an obtained mixture to obtain the hyaluronic acid oligosaccharide encased paclitaxel liposome. The oligosaccharide encased paclitaxel liposome is uniform in size, high in encapsulation rate and stable in property; and the solubility of paclitaxel in water is effectively improved. Furthermore, for CD44 high-expression cancer cells (such as the breast cancer), the compound has relatively high targeting (hyaluronic acid is capable of specifically combining with CD44); the concentration of paclitaxel on a tumor part can be effectively increased; the using amount of paclitaxel is reduced; and the toxicity of a medicine on a human body is reduced, and the biological utilization rate is enhanced.

The invention provides a paclitaxel liposome composition for injection prepared through a novel freeze-drying method, and particularly relates to the paclitaxel liposome composition for injection, which is short in freeze-drying period, low in cost, stable and uniform in quality, excellent in product appearance and suitable for production. The process of the composition is simple, the preparation is stable after freeze-drying and is favorable for industrial production, the production cost is lowered, the fluctuation change of the grain size of the liposome is avoided, the pharmacological effects are guaranteed, and the safety of clinical medication is improved.

The invention confirms the suppression effect of paclitaxel liposome on B cell proliferation and immunologic function, and the application of paclitaxel liposome on rat CIA treatment.

The invention discloses a biotin and cell-penetrating peptide co-mediated breast cancer targeted intelligent liposome material. The intelligent liposome material is prepared by the following steps: 1,modifying biotin on a PEG long chain, and connecting the biotin with cholest through an acid-sensitive bond (a general formula I, a ligand material a); and 2, connecting cell-penetrating peptide R8 with phospholipid through Michael addition reaction (a formula II and a ligand material b). After the two ligand materials are combined to prepare a liposome, the biotin exposed on the surface of the liposome can specifically recognize an overexpressed SMVT transporter on the surface of a breast cancer cell; and after the liposome reaches the breast tumor part, a PEG long chain connected with a hydrazone bond is broken and separated, and the R8 connected with a short chain is mediated, passes through membrane and enters the cell, so that the effect of strongly treating the breast cancer is realized. The novel intelligent liposome material can be used for different dosage forms including liposome, nanoparticles, micelles and the like, and a prepared paclitaxel-loaded liposome has strong breast cancer penetrability and treatment effect and has a wide application prospect.

The invention relates to the technical field of liposome processing and specifically discloses an evaporation drying device for paclitaxel liposome. The evaporation drying device comprises a bottle clamp, an evaporation tube and a rubber sealing layer located on an outer wall of the evaporation tube; the middle or upper part of the rubber sealing layer is bulged outward so as to form a bulged ring; the bottle clamp comprises a first C-shaped clamping wall and a second C-shaped clamping wall located under the first C-shaped clamping wall; a connecting strip is arranged between the first C-shaped clamping wall and the second C-shaped clamping wall; a counterweight bulge is arranged on the inner side of the first C-shaped clamping wall. The scheme is capable of solving the problem in the prior art that leakage accident is likely to occur because the rotating bottle and the evaporation tube are sealed through the contact of respective rubber sealing layers.